Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
2005 · Journal of Clinical Oncology · 364 citations
https://doi.org/10.1200/jco.2005.12.157